A randomized, multicenter, Phase 3, observer-blind, active-controlled trial of ARCT-2301 in Japan
Latest Information Update: 08 Oct 2024
At a glance
- Drugs ARCT 2301 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 08 Oct 2024 Status changed from not stated to recruiting.
- 08 Oct 2024 New trial record
- 30 Sep 2024 Results (Between September and November 2023, n=930) presented in the CSL Media Release.